DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Efficacy/Safety Study of Amaryl®M 1/500 mg Twice Daily Versus Amaryl® 4 mg Both in Combination With Lantus® in Type 2 Diabetes Mellitus

Information source: Handok Pharmaceuticals Co., Ltd.
Information obtained from ClinicalTrials.gov on February 07, 2013
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Type 2 Diabetes Mellitus

Intervention: glimepiride + insulin glargine (Amaryl + Lantus) (Drug); glimepiride/metformin fixed combination+insulin glargine (AmarylM + Lantus) (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: Handok Pharmaceuticals Co., Ltd.

Official(s) and/or principal investigator(s):
Kang S Park, Principal Investigator, Affiliation: Eulji University Hospital

Summary

The purpose of this study is to compare the efficacy of AmarylM 1/500 mg twice daily versus Amaryl 4 mg both in combination with Lantus once-daily regimen in type 2 Diabetes Mellitus patients with inadequate glycemic control.

Clinical Details

Official title: A Multi-Center, Open, Randomized, Parallel-Group, 2 Arm Study to Compare the Efficacy and Safety of AmarylM 1/500mg Twice Daily Versus Amaryl 4mg Both in Combination With Lantus Once-Daily Regimen in Type 2 Diabetes Mellitus Patients With Inadequate Glycemic Control

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Mean change in HbA1c from baseline to the last visit

Secondary outcome:

Mean change in FPG, insulin, c-peptide from baseline to the last visit Safety; Episodes of hypoglycemia & other adverse events

Response rate based on HbA1c and FPG levels measured at the last visit

Mean change in Lantus® dose from baseline to the last visit

Compliance

Frequency with hypoglycemic episode

Adverse events

Detailed description: There are several kinds of oral antidiabetic drugs (OADs) that are used in the treatment of patients with type 2 DM. Among them, sulfonylurea and metformin are well-established first-line OADs. However, as the beta cell dysfunction progresses over time, patients fail to achieve good glycemic control with OADs alone and need further treatment intensification, usually involving the introduction of insulin either alone or in combination with OADs. Now, an OAD combined with bedtime insulin is one of the recommended treatment options for patients with type 2 DM and OAD failure. But, it still remains unclear which OADs are the most effective in combination with insulin for the treatment of type 2 DM.

so, this study we will be able to verify which OADs are the most effective in combination with insulin for the treatment of type 2 DM.

Eligibility

Minimum age: 20 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients over 20 years old with type 2 DM

- Patients with inadequate glycemic control despite continuous use of tolerable or

maximal doses of one or more OADs for 3months or more.

- 7%

- 21 kg/m2 ≤ BMI ≤ 30 kg/m2

- Patents who need insulin add-on therapy based on investigator's discretion

- Patients who would give the informed consent

- Patients who can perform SMBG and record the data on the patient's diary

Exclusion Criteria:

- History of acute metabolic complications such as diabetic ketoacidosis or

hyperosmolar nonketotic coma within 3 months before screening

- Pregnant or lactating females

- History of drug or alcohol abuse

- Patients with known hypersensitivity to glimepiride, metformin HCL or insulin

- Night-shift workers

- Patients who are under insulin therapy at screening

- Treatment with any investigational products in the last 3 months before screening

- Clinically significant laboratory abnormality on screening labs or any medical

condition that would affect the completion or outcome of the study based on investigator's decision

- Patients with serum creatinine level > 1. 5 mg/dl in male and > 1. 4 mg/dl in female

- Patients with ALT or AST > 3x ULN

Locations and Contacts

Ji Young Kim, Seoul, Korea, Republic of; Recruiting
Ji Y Kim, Phone: 82-2-527-5553, Email: JiYoung4.Kim@handok.com
Additional Information

Starting date: May 2009
Last updated: June 2, 2009

Page last updated: February 07, 2013

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014